Psychiatr. pro Praxi, 2008; 9(3): 121-124

Cognitive disorders in patients with vascular brain disease

MUDr. David Goldemund, PhDr. Sabina Telecká
I. neurologická klinika LF MU a FN u sv. Anny Brno

Cognitive disorders in patients with vascular brain disease are relatively frequent. In spite of the significantly negative influence on quality of life, they remain often unrecognized and untreated. The authors discuss a brief review of ethiopathogenesis, diagnostics and treatment of vascular cognitive disorders.

Keywords: vascular brain disease, vascular cognitive deficit, dementia, early diagnosis, depression

Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Goldemund D, Telecká S. Cognitive disorders in patients with vascular brain disease. Psychiatr. praxi. 2008;9(3):121-124.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke, 1994; 25(6): 1099-1104. Go to original source... Go to PubMed...
    2. Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database Syst Rev, 2003(3): p. CD003154. Go to original source...
    3. Black S. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke, 2003; 34(10): 2323-2330. Go to original source... Go to PubMed...
    4. Clarke P et al. Well-being after stroke in Canadian seniors: findings from the Canadian study of health and aging. Stroke, 2002; 33(4): 1016-1021. Go to original source... Go to PubMed...
    5. Erkinjuntti T et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl, 2000; 59: 23-30. Go to original source... Go to PubMed...
    6. Erkinjuntti T et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet, 2002; 359(9314): 1283-1290. Go to original source... Go to PubMed...
    7. Folstein MF, Folstein SE and PR. McHugh., ,Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 1975; 12(3): 189-198. Go to original source... Go to PubMed...
    8. Hachinski V. Vascular dementia: a radical redefinition. Dementia, 1994; 5(3-4): 130-132. Go to original source... Go to PubMed...
    9. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol, 2007; 6(9): 782-792. Go to original source... Go to PubMed...
    10. Moretti R et al. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen, 2003; 18(5): 265-272. Go to original source... Go to PubMed...
    11. Pohjasvaara T et al. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences. Stroke, 2000; 31(12): 2952-2957. Go to original source... Go to PubMed...
    12. Roman GC et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology, 1993; 43(2): 250-260. Go to original source... Go to PubMed...
    13. Snowdon DA et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. Jama, 1997; 277(10): 813-817. Go to original source...
    14. Wiart L et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke, 2000; 31(8): 1829-1832. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.